Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 4/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9101487 | 1.00 | CYP1A1 (0.50) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 | |
| SCHEMBL19385627 | 0.95 | NR4A1 (0.54) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 | |
| SCHEMBL19385642 | 0.95 | NR4A1 (0.54) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 | |
| SCHEMBL24249396 | 0.80 | SMN1; SMN2 (0.50) | CYP1A1CYP1B1PTPN1GSK3B | |
| SCHEMBL15489063 | 0.80 | NPSR1 (0.49) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 | |
| SCHEMBL17077250 | 0.80 | NR4A1 (0.50) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 | |
| SCHEMBL15556233 | 0.80 | NR4A1 (0.50) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 | |
| SCHEMBL17077251 | 0.80 | NR4A1 (0.50) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 | |
| SCHEMBL13864065 | 0.79 | NFE2L2 (0.59) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 | |
| SCHEMBL8534180 | 0.78 | CYP1A1 (0.46) | CYP1A1CYP1B1NR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2642856-B1 | INTEGRIN-LINKED KINASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8658647-B2 | Integrin-linked kinase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2642856-A1 | INTEGRIN-LINKED KINASE INHIBITORS | The Ohio State University Research Foundation (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20120142702-A1 | INTEGRIN-LINKED KINASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012071310-A1 | INTEGRIN-LINKED KINASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142702-A1 | INTEGRIN-LINKED KINASE INHIBITORS | PTK2, ITGB1, ITGB2 | CYP1A1 4727/4885CYP1B1 4318/4885NR4A1 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.